About PregLem
PregLem is a Healthcare company based in Geneve (Switzerland) founded in 2006, and was acquired by Gedeon Richter in October 2010. Innovative drugs for womens reproductive medicine are developed and commercialized. PregLem has raised $57.94 million across 2 funding rounds from investors including MVM Partners, Sofinnova and NeoMed. Its focus areas include Life Sciences, Women Health, Drugs and Reproductive Diseases.
Company details
PregLem is dedicated to the development and commercialization of innovative drugs for womens reproductive medicine. It markets ESMYA (ulipristal acetate), an oral selective progesterone receptor modulator (SPRM) for long-term management of uterine fibroids. Its drug pipeline includes PGL2001, an oral, once-a-week steroid sulfatase inhibitor (STS-I) being developed for the management of endometriosis, including the relief of pain associated with the condition (Phase 2a); PGL1001, a somatostatin antagonist (SST-ATG) with the potential to accelerate the recruitment of resting follicles from the ovarian follicular reserve (preclinical)
- Headquarters Geneve, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website preglem.com
- Social LinkedIn
- Acquired by Gedeon Richter (Oct 2010)
- Total Equity Funding$57.94M (USD)
in 2 rounds
- Latest Funding Round$31.89M (USD), Series B
Dec 2007
- InvestorsMVM Partners
& 4 more
- Acquired byGedeon Richter
(Oct 2010)
Funding Insights of PregLem
PregLem has successfully raised a total of $57.94M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $31.89 million completed in December 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $57.94M
- Total Rounds 2
- Last Round Series B — $31.89M
- First Round $26.05M
(Jun 2007)
- Investors Count 4
All 2 funding rounds of PregLem with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2007 | $31.89M | Series B | – | Sofinnova Investments | |
| Jun 2007 | $26.05M | Series A | – | NeoMed, MVM | – |
5 investors in total: 5 institutional.
Investors in PregLem
PregLem has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include MVM Partners, Sofinnova and NeoMed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Private equity investments in healthcare companies are managed. | 1997 | mvm.com | London, United Kingdom | |
Stage-agnostic life sciences-focused VC firm investing in North America & Europe | neomed.net | Oslo, Norway | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Pharmaceutical manufacturing, research, and marketing in Hungary. | richter.hu |
Investor details for PregLem
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PregLem
35 people are tracked at PregLem (3 in leadership, 32 in team).
| Name | Role | Group |
|---|---|---|
J.pierre N. | Finance Director | Leadership |
Clive Scragg | Business Unit Director | Leadership |
Heike Kenngott | Vice President Regulatory Affairs | Leadership |
Karla Susana Cedillo Palos | Representante De Ventas | Team |
Emilie Genetelli | Visiteur Médical | Team |
Andreea Puscas | Brand Manager | Team |
Kieron Beard | Accountant | Team |
Marcelo Maturana Parada | Representante | Team |
Svetlin Stoilov | Senior Medical Representative | Team |
Cecilia Lindborg | Key Account Manager | Team |
Ana Belen Herrero | Key Account Manager Fertility Unit | Team |
Michelle Gridley | Key Account Manager | Team |
Kerstin Winter | Key Account Manager | Team |
Manuela Correia | Key Account | Team |
Phil Jones | Key Account Manager Womens Health | Team |
Julian Ellis | Key Account Manager | Team |
Atanas Statev | Medical Representative Product Responsibilities | Team |
Cinzia Tarini | Medical Science Liaison | Team |
Gemma Platas Guitart | Delegada Visita Médica - Ginecología | Team |
Grimaldi Giuseppe | Informatore Medico Scientifico | Team |
15 more people are available in the full profile.
Complete people profiles for PregLem
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PregLem
4 dated milestones of PregLem across 4 years, from founding to its latest funding, stage changes and deals.
- Founded PregLem is founded.
- Funding First funding round of $26.0M.
- Funding Latest funding round, Series B, of $31.9M.
- Exit Acquired by Gedeon Richter.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PregLem
PregLem was founded in 2006 and raised its 1st funding round 1 year after it was founded.
PregLem is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
PregLem is a funded company, having raised a total of $57.94M across 2 funding rounds to date. The company's 1st funding round was a Series A of $26.05M, raised on Jun 2007.
PregLem is dedicated to the development and commercialization of innovative drugs for womens reproductive medicine. It markets ESMYA (ulipristal acetate), an oral selective progesterone receptor modulator (SPRM) for long-term management of uterine fibroids. Its drug pipeline includes PGL2001, an oral, once-a-week steroid sulfatase inhibitor (STS-I) being developed for the management of endometriosis, including the relief of pain associated with the condition (Phase 2a); PGL1001, a somatostatin antagonist (SST-ATG) with the potential to accelerate the recruitment of resting follicles from the ovarian follicular reserve (preclinical).
PregLem has 5 investors. Key investors include MVM Partners, Sofinnova, NeoMed, Sofinnova Partners, and Richter Gedeon.
Yes. PregLem was acquired by Gedeon Richter in October 2010.